Pavel Kapysh / Shutterstock.com
A subsidiary of India’s Sun Pharma has agreed to pay more than $200 million to settle charges related to a generics price-fixing investigation.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Generics, Sun Pharma, Taro, Sandoz, price-fixing, antitrust, DoJ, prosecutors, charges, investigation